Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 101; no. 3; pp. 263 - 265
Main Authors Pospisilova, Sarka, Sutton, Lesley-Ann, Malcikova, Jitka, Tausch, Eugen, Rossi, Davide, Montserrat, Emili, Moreno, Carol, Stamatopoulos, Kostas, Gaidano, Gianluca, Rosenquist, Richard, Ghia, Paolo
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 01.03.2016
Subjects
Agammaglobulinaemia Tyrosine Kinase
Alleles
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors
Class I Phosphatidylinositol 3-Kinases - genetics
Class I Phosphatidylinositol 3-Kinases - metabolism
Gene Expression
Gene Frequency
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Medicin och hälsovetenskap
Molecular Targeted Therapy
Prognosis
Protein-Tyrosine Kinases - antagonists & inhibitors
Protein-Tyrosine Kinases - genetics
Protein-Tyrosine Kinases - metabolism
Purines - therapeutic use
Pyrazoles - therapeutic use
Pyrimidines - therapeutic use
Quinazolinones - therapeutic use
Sulfonamides - therapeutic use
Tumor Suppressor Protein p53 - deficiency
Tumor Suppressor Protein p53 - genetics
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-3
Contributed equally as senior author
Contributed equally as first author
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2015.139246